Lymphoma & Leukemia Program
About Lymphoma and Leukemia
Since lymphoma is a cancer of the immune system, a major scientific goal of the Lymphoma and Leukemia Program is to use knowledge gained from immunology to understand and treat lymphoid malignancies. This goal is being accomplished by gaining better understanding of the biology underlying lymphoid and myeloid neoplasms and applying this knowledge to improve the diagnosis and treatment of these disorders.
- Discover the Genetic and Cellular Origins of Lymphomas and Leukemias
- Develop Novel Methods of Diagnosis and Biomarker Monitoring of these Diseases
- Develop New Therapies
Lymphoma and Leukemia Clinical Trials
Stanford is currently accepting patients for this trial.
Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell MalignanciesStanford is currently accepting patients for this trial.
A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid LeukemiaStanford is currently accepting patients for this trial.
Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell LymphomaStanford is currently accepting patients for this trial.